FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029506306> ?p ?o ?g. }

• W2029506306 endingPage "533" @default.
• W2029506306 startingPage "528" @default.
• W2029506306 abstract "The purpose of this study was to evaluate in a phase I-II trial whether low doses of recombinant human interleukin 2 (rHuIL-2) over a prolonged period of time are safe and effective in eradicating or controlling minimal residual disease in children with neuroblastoma given high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT). From January 1992 to July 1996, 17 consecutive patients, with either stage IV or relapsed neuroblastoma, were enrolled. Patients received rHuIL-2 after a median time interval (min-max) of 105 days (56-153) after HDCT and ASCT. The protocol consisted of 2 'priming' courses of rHuIL-2 at escalating doses administered intravenously at 72-h intervals, followed by 'maintenance' with 11 monthly and six bimonthly boosting 5-day courses administered subcutaneously on an outpatient basis. At April 1997, 7 out of the 17 patients had completed the treatment schedule, four had discontinued treatment because of toxicity and four because of relapse; the remaining two patients are still on treatment, having completed 15 courses. Expansion of T lymphocytes, together with an increase in both natural killer cells and in activated T lymphocytes was evidenced. After a median (min-max) follow-up time of 30 (16-64) months, 12 out of 17 patients are alive and well. Two patients relapsed and died 14 and 35 months after transplant. Three patients are alive after having relapsed at 41, 21 and 13 months. The actuarial 2-year event-free survival and overall survival are 67% and 92% respectively. Intermittent administration of low doses of rHuIL-2 given for a long period of time is well tolerated and seems capable of controlling minimal residual disease after HDCT and ASCT in children with high-risk neuroblastoma." @default.
• W2029506306 created "2016-06-24" @default.
• W2029506306 creator A5022712318 @default.
• W2029506306 creator A5036782170 @default.
• W2029506306 creator A5050104358 @default.
• W2029506306 creator A5053084258 @default.
• W2029506306 creator A5059413304 @default.
• W2029506306 creator A5064250407 @default.
• W2029506306 creator A5073523995 @default.
• W2029506306 creator A5074034025 @default.
• W2029506306 creator A5078844162 @default.
• W2029506306 date "1998-08-01" @default.
• W2029506306 modified "2023-10-06" @default.
• W2029506306 title "Immunotherapy with low-dose recombinant interleukin 2 after high-dose chemotherapy and autologous stem cell transplantation in neuroblastoma" @default.
• W2029506306 cites W109754485 @default.
• W2029506306 cites W1516671033 @default.
• W2029506306 cites W1592924232 @default.
• W2029506306 cites W1605088744 @default.
• W2029506306 cites W1831752343 @default.
• W2029506306 cites W1868595314 @default.
• W2029506306 cites W1892022085 @default.
• W2029506306 cites W2030162473 @default.
• W2029506306 cites W2035763080 @default.
• W2029506306 cites W2044674177 @default.
• W2029506306 cites W2064168698 @default.
• W2029506306 cites W2067925808 @default.
• W2029506306 cites W2110695295 @default.
• W2029506306 cites W2253902778 @default.
• W2029506306 cites W2405990756 @default.
• W2029506306 cites W2415524025 @default.
• W2029506306 cites W2417799216 @default.
• W2029506306 cites W2419291966 @default.
• W2029506306 cites W2419569360 @default.
• W2029506306 doi "https://doi.org/10.1038/bjc.1998.527" @default.
• W2029506306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2063104" @default.
• W2029506306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9716039" @default.
• W2029506306 hasPublicationYear "1998" @default.
• W2029506306 type Work @default.
• W2029506306 sameAs 2029506306 @default.
• W2029506306 citedByCount "29" @default.
• W2029506306 countsByYear W20295063062012 @default.
• W2029506306 countsByYear W20295063062015 @default.
• W2029506306 countsByYear W20295063062017 @default.
• W2029506306 countsByYear W20295063062023 @default.
• W2029506306 crossrefType "journal-article" @default.
• W2029506306 hasAuthorship W2029506306A5022712318 @default.
• W2029506306 hasAuthorship W2029506306A5036782170 @default.
• W2029506306 hasAuthorship W2029506306A5050104358 @default.
• W2029506306 hasAuthorship W2029506306A5053084258 @default.
• W2029506306 hasAuthorship W2029506306A5059413304 @default.
• W2029506306 hasAuthorship W2029506306A5064250407 @default.
• W2029506306 hasAuthorship W2029506306A5073523995 @default.
• W2029506306 hasAuthorship W2029506306A5074034025 @default.
• W2029506306 hasAuthorship W2029506306A5078844162 @default.
• W2029506306 hasBestOaLocation W20295063061 @default.
• W2029506306 hasConcept C121608353 @default.
• W2029506306 hasConcept C126322002 @default.
• W2029506306 hasConcept C141071460 @default.
• W2029506306 hasConcept C2776694085 @default.
• W2029506306 hasConcept C2776715637 @default.
• W2029506306 hasConcept C2777701055 @default.
• W2029506306 hasConcept C2778461978 @default.
• W2029506306 hasConcept C2779050716 @default.
• W2029506306 hasConcept C2779823535 @default.
• W2029506306 hasConcept C2911091166 @default.
• W2029506306 hasConcept C54355233 @default.
• W2029506306 hasConcept C71924100 @default.
• W2029506306 hasConcept C81885089 @default.
• W2029506306 hasConcept C86803240 @default.
• W2029506306 hasConceptScore W2029506306C121608353 @default.
• W2029506306 hasConceptScore W2029506306C126322002 @default.
• W2029506306 hasConceptScore W2029506306C141071460 @default.
• W2029506306 hasConceptScore W2029506306C2776694085 @default.
• W2029506306 hasConceptScore W2029506306C2776715637 @default.
• W2029506306 hasConceptScore W2029506306C2777701055 @default.
• W2029506306 hasConceptScore W2029506306C2778461978 @default.
• W2029506306 hasConceptScore W2029506306C2779050716 @default.
• W2029506306 hasConceptScore W2029506306C2779823535 @default.
• W2029506306 hasConceptScore W2029506306C2911091166 @default.
• W2029506306 hasConceptScore W2029506306C54355233 @default.
• W2029506306 hasConceptScore W2029506306C71924100 @default.
• W2029506306 hasConceptScore W2029506306C81885089 @default.
• W2029506306 hasConceptScore W2029506306C86803240 @default.
• W2029506306 hasIssue "4" @default.
• W2029506306 hasLocation W20295063061 @default.
• W2029506306 hasLocation W20295063062 @default.
• W2029506306 hasLocation W20295063063 @default.
• W2029506306 hasLocation W20295063064 @default.
• W2029506306 hasOpenAccess W2029506306 @default.
• W2029506306 hasPrimaryLocation W20295063061 @default.
• W2029506306 hasRelatedWork W110863184 @default.
• W2029506306 hasRelatedWork W1930151598 @default.
• W2029506306 hasRelatedWork W2021673773 @default.
• W2029506306 hasRelatedWork W2037692246 @default.
• W2029506306 hasRelatedWork W2332089335 @default.
• W2029506306 hasRelatedWork W2388571378 @default.
• W2029506306 hasRelatedWork W2406723506 @default.
• W2029506306 hasRelatedWork W2442701572 @default.

• next